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376 Letters to the Editor
Abdominal aortic aneurysm
and autosomal-dominant
polycystic kidney disease
To the Editor: In a recent issue of Kidney International,
Gibbs et al [1] ascertained the risk of growth and rup-
ture of intracranial aneurysms in autosomal-dominant
polycystic kidney disease (ADPKD) patients discov-
ered by presymptomatic screening. It is well known that
ADPKD is associated with a variety of life-threatening
cardiovascular diseases, such as intracranial and coronary
aneurysms [2]. On the other hand, the coexistence of ab-
dominal aortic aneurysm (AAA) has been also reported
in some ADPKD patients [2–5]. Chapman and Hilson
[3] have described three patients (9.7%) with AAA and
polycystic renal failure out of a total 31 patients with
adult polycystic disease who had been on their dialysis
and transplantation program for some time. Roodvoets
[4] has reported an AAA in 1 (5.0%) of 20 patients with
polycystic kidney disease. Kato et al [2] have reported
that the frequency of AAA was 7.1% in ADPKD pa-
tients. Ruptured AAA has been also described [3, 4], and
the technical difficulty of the exposure of the aorta is in-
creased by the presence of voluminous kidneys, causing
delay in cross-clamping during emergency laparotomy for
rupture [5]. A significant increase in the aortic diame-
ters (2.7 ± 0.14 cm) was found in the ADPKD patients
compared with those in the chronic glomerulonephritis
(2.3 ± 0.03 cm) and diabetes mellitus (2.3 ± 0.05 cm)
groups (P < 0.02), and a routine screening of the aortic
size, using computed tomography or echography, is rec-
ommended to detect the presence of AAA in ADPKD
patients [2]. Further studies of screening and follow-up
of AAA in ADPKD patients are needed.
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Fig. 1. Weekly doses of vitamin C derived from recommended daily
allowance for the general population, compared with dosages suggested
for patients on chronic dialysis. From references [1–4].
Protective effect of vitamin C
supplementation in dialysis
patients: Not all that glitters. . .
To the Editor: An elegant study by Tarng et al [1] has
demonstrated that intravenous vitamin C supplementa-
tion as 300 mg postdialysis three times a week reduces
DNA-8-hydroxy-2′deoxyguanosine and reactive oxygen
species in peripheral lymphocytes of dialysis patients.
Its efficacy with serum ferritin < and >500 lg/L speaks
against the worried pro-oxidant effect of vitamin C on
lymphocyte DNA oxidation in case of increased iron
stores.
What would be the actual consequences of introducing
this knowledge in the clinical practice? As in previous
works on erythropoietin therapy, vitamin C as “adjuvant
therapy” at dosages many times higher than that sug-
gested for the general population became recommended
in dialysis patients (Fig. 1), without putting evidence
forward to demonstrate the safety in terms of oxalate
metabolism [2–4].
Major concern for safety of vitamin C supplementation
arises from its metabolism to oxalate, which, in uremic pa-
tients, may exceed the threshold of solubility of calcium
oxalate, and result in tissue deposition of calcium oxalate
crystals, eventually increasing cardiovascular risks and
worsening renal function in predialysis patients.
The gap between theoretical knowledge and actual
demonstration of benefits in major outcomes such as sur-
vival often being large, the ratio “known side effects/
unknown clinical benefits” should be carefully evaluated
